Health Dictionary

Overview

Cerebral palsy must be differentiated from other diseases that cause spasticity, hypotonia, ataxia, and dystonia such as inherited metabolic disorders, intellectual disability, metabolic myopathies, metabolic neuropathy, traumatic peripheral nerve lesions, tumors of the conus and cauda equina and vascular malformations of the spinal cord.

Differentiating Cerebral Palsy from other Diseases

Cerebral Palsy must be differentiated from other slowly progressive diseases such as neurodegenerative disease or metabolic disorders.^[1]^[2]^[3]^[4]
Presence of any of the following factors may suggest an alternative diagnosis:^[5]
- Family history of any CNS disease
- Progressive worsening of neurological symptoms
- Symptoms worsened during stress such as illness or fasting
- Absence of any specific risk factor causing cerebral palsy
- Hypotonia with weakness
- Failure to develop milestones normally
- Clinical findings such as muscle atrophy, ataxia, sensory disturbances and involuntary movements
Cerebral palsy must be differentiated from
- Inherited metabolic disorders
- Intellectual disability
- Metabolic myopathies
- Metabolic neuropathy
- Traumatic peripheral nerve lesions
- Tumors of the Conus and Cauda equina
- Vascular malformations of the spinal cord

Preferred Table

Diseases	Type of motor abnormality				Clinical findings	Laboratory findings and diagnostic tests	Radiographic findings
Diseases	Spasticity	Hypotonia	Ataxia	Dystonia	Clinical findings	Laboratory findings and diagnostic tests	Radiographic findings
Leigh syndrome	–	–	+	+	Progressive psychomotor regression Seizures External ophthalmoplegia Lactic acidosis Vomiting	Increased lactate levels in blood and CSF Genetic testing	MRI: abnormal white matter signal in the putamen, basal ganglia, and brainstem on T2 images
Niemann-Pick disease type C	–	–	+	+	Progressive neurodegeneration Hepatosplenomegaly Systemic involvement of liver, spleen, or lung preceedes neurologic symptoms	Abnormal liver function tests Fibroblast cell culture with filipin staining	MRI: Cerebral and cerebellar atrophy Thinning of the corpus callosum
Infantile Refsum disease	–	+	+	–	Abnormalities of the optic nerve and disc Retinitis pigmentosa Sensorineural hearing loss Hepatomegaly and cirrhosis Neurologic deterioration is slower than in Zellweger syndrome or ALD	Elevated plasma VLCFA levels	—
Adrenoleukodystrophy	+	–	–	–	Cognitive and behavioral abnormalities Adrenal insufficiency Hyperpigmented skin Gonadal dysfunction Neurologic deterioration progresses at a variable rate	Elevated plasma VLCFA levels Molecular genetic testing for mutations in the ABCD1 gene	—
Zellweger syndrome	–	+	–	–	Craniofacial dysmorphism Hepatomegaly Neonatal seizures Profound developmental delay MRI findings include cortical and white matter abnormalities Neurologic deterioration is rapid and infants rarely survive beyond six months of age	Elevated plasma VLCFA levels Elevated levels of phytanic acid, pristanic acid, and pipecolic acid in plasma and fibroblasts Reduced plasmalogen in erythrocytes Molecular genetic testing for mutations in the PEX1 or PEX6 genes	—
Pyruvate dehydrogenase deficiency	+	+	+	–	Lactic acidosis Seizures Intellectual disability	Elevated lactate and pyruvate levels in blood and CSF Abnormal PDH enzymatic activity in cultured fibroblasts	—
Arginase deficiency	+	–	–	–	Hyperammonemia Encephalopathy Respiratory alkalosis	Elevated ammonia level Elevated arginine level	—
Holocarboxylase synthetase deficiency	–	+	–	–	Ketoacidosis Dermatitis Alopecia Seizures Developmental delay	Elevated levels of: Beta-hydroxyisovalerate Beta-methylcrotonylglycine Beta-hydroxypropionate Methylcitrate Tiglylglycine	—
Glutaric aciduria type 1	–	–	–	+	Episodes of metabolic decompensation and encephalopathy often precipitated by infection and fever Rarely presents in the newborn period Microencephalic macrocephaly Seizures (approximately 20 percent) Cognitive function is preserved	Elevated levels of: glutaric acid 3-hydroxyglutaric acid	MRI: Frontal and temporal atrophy
Ataxia telangiectasia	–	–	+	–	Progressive cerebellar ataxia Abnormal eye movements Oculocutaneous telangiectasias Immune deficiency Increased risk of malignancy	Elevated serum alpha-fetoprotein level Low IgA and IgG levels Lymphopenia Genetic testing for mutation in the ATM gene	—
Pontocerebellar hypoplasias	–	+	–	–	Progressive muscle atrophy Microcephaly Developmental delay	Genetic testing for PCH gene mutations	MRI : Small cerebellum and brainstem including the pons
Metachromatic leukodystrophy	–	+	+	–	Regression of motor skills Seizures Optic atrophy Reduced or absent deep tendon reflexes Intellectual disability	Deficient arylsulfatase A enzyme activity in leukocytes or cultured skin fibroblasts	—
Pelizaeus-Merzbacher	+	–	+	–	Nystagmus Cognitive impairment Onset in infancy Slowly progressive Language development may be normal	Genetic testing for mutations in PLP1 gene	MRI: White matter abnormalities
Angelman syndrome	–	–	+	–	Profound intellectual disability Postnatal microcephaly Typical abnormal behaviors (paroxysmal laughter, easily excitable)	Methylation studies and chromosome microarray to detect chromosome 15 anomalies and UBE3A mutations	—
Rett syndrome	+	–	–	+	Occurs almost exclusively in females Normal development during first six months followed by regression and loss of milestones Loss of speech capability Stereotypic hand movements Seizures Autistic features	Clinical diagnosis Genetic testing for MECP2 mutations	—
Lesch-Nyhan syndrome	+	–	–	+	Self-mutilating behavior Urinary stones due to hyperuricemia	Elevated uric acid level Abnormal enzymatic activity of HPRT in cultured fibroblasts Genetic testing for HPRT gene mutations	—
Miller-Dieker lissencephaly	+	+	–	–	Lissencephaly Microcephaly Dysmorphic features Seizures Failure to thrive	Cytogenetic testing for 17p13.3 microdeletion	—
Dopa-responsive dystonia	+	–	–	+	Onset in early childhood Symptoms worsen with fatigue and exercise	Positive response to a trial of levodopa	—

References

↑ Cooper J, Majnemer A, Rosenblatt B, Birnbaum R (1995). “The determination of sensory deficits in children with hemiplegic cerebral palsy”. J. Child Neurol. 10 (4): 300–9. doi:10.1177/088307389501000412. PMID 7594266.
↑ Himmelmann K, Beckung E, Hagberg G, Uvebrant P (2006). “Gross and fine motor function and accompanying impairments in cerebral palsy”. Dev Med Child Neurol. 48 (6): 417–23. doi:10.1017/S0012162206000922. PMID 16700930.
↑ Odding E, Roebroeck ME, Stam HJ (2006). “The epidemiology of cerebral palsy: incidence, impairments and risk factors”. Disabil Rehabil. 28 (4): 183–91. doi:10.1080/09638280500158422. PMID 16467053.
↑ Burns YR, O’Callaghan M, Tudehope DI (1989). “Early identification of cerebral palsy in high risk infants”. Aust Paediatr J. 25 (4): 215–9. PMID 2590117.
↑ Gupta R, Appleton RE (2001). “Cerebral palsy: not always what it seems”. Arch. Dis. Child. 85 (5): 356–60. PMC 1718969. PMID 11668092.

[pmid7594266-1] Cooper J, Majnemer A, Rosenblatt B, Birnbaum R (1995). “The determination of sensory deficits in children with hemiplegic cerebral palsy”. J. Child Neurol. 10 (4): 300–9. doi:10.1177/088307389501000412. PMID 7594266.

[pmid16700930-2] Himmelmann K, Beckung E, Hagberg G, Uvebrant P (2006). “Gross and fine motor function and accompanying impairments in cerebral palsy”. Dev Med Child Neurol. 48 (6): 417–23. doi:10.1017/S0012162206000922. PMID 16700930.

[pmid16467053-3] Odding E, Roebroeck ME, Stam HJ (2006). “The epidemiology of cerebral palsy: incidence, impairments and risk factors”. Disabil Rehabil. 28 (4): 183–91. doi:10.1080/09638280500158422. PMID 16467053.

[pmid2590117-4] Burns YR, O’Callaghan M, Tudehope DI (1989). “Early identification of cerebral palsy in high risk infants”. Aust Paediatr J. 25 (4): 215–9. PMID 2590117.

[pmid11668092-5] Gupta R, Appleton RE (2001). “Cerebral palsy: not always what it seems”. Arch. Dis. Child. 85 (5): 356–60. PMC 1718969. PMID 11668092.

[1]

[2]

[3]

[4]

[5]

Health Dictionary

Cerebral palsy differential diagnosis

Introduction

Overview

Differentiating Cerebral Palsy from other Diseases

Preferred Table

References